louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT04433962: Investigation of the Effects of Balance Training on Balance and Functional Status Patients With Total Hip Arthroplasty
Official title: Investigation of the Effects of Balance Training on Balance and Functional Status Patients With Total Hip Arthroplasty
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Arthroplasty Complications
Physical Disability
Osteoarthritis, Hip
Keywords: osteoarthritis
hip
total hip arthroplasty
balance training
function
assessment
Lead sponsor: Ege University
Sponsor class: OTHER
First posted: 2020-06-16
Enrollment: 32
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to investigate the effects of balance training in patients with THA until 26 weeks postoperatively. Thirty-two patients with hip osteoarthritis who were candidates for THA were recruited to the study. Sixteen patients with THA completed the study protocol and the patients were randomized into 2 groups: conventional rehabilitation (CR, n=8) or conventional rehabilitation plus balance training (CR + BT, n=8) groups. The patients were evaluated by hand-held dynamometer, single leg stance test (SLST), Tetrax balance system, Harris hip score, lower extremity function scale, 5 times sit-to-stand test and 50 foot timed walk test preoperatively and in the 8th, 14th and 26th weeks postoperatively.


Eligibility criteria: Inclusion Criteria:

* Total hip arthroplasty due to osteoarthritis
* First time hip surgery/prothesis
* no involvement in any exercise program in the past 12 months

Exclusion Criteria:

* THA due to hip fracture,
* revision hip prothesis,
* arthritis in other joints limited function
* neurologic problems that limited function and balance,
* body mass index greater than 40 kg/m2.

Primary outcomes:
measure: single leg test
timeFrame: Pre-op to post-op 26. week
measure: Tetrax Balance Assessment
timeFrame: Pre-op to post-op 26. week
measure: Sit to stand test
timeFrame: Pre-op to post-op 26. week
measure: 50 feet walk test
timeFrame: Pre-op to post-op 26. week
measure: Harris hip score
timeFrame: Pre-op to post-op 26. week
measure: Lower extremity function scale
timeFrame: Pre-op to post-op 26. week
Secondary outcomes:
measure: Pain assessment
timeFrame: Pre-op to post-op 26. week
measure: Range of motion
timeFrame: Pre-op to post-op 26. week
measure: Muscle strength
timeFrame: Pre-op to post-op 26. week
Other outcomes:
Locations:
city: Izmir
country: Turkey
facility: Dokuz Eylul University
state: Bornova
Study officials:
affiliation: Ege University
name: Nuray Elibol, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02233062: Impact of Exclusive Enteral Nutrition Therapy on Sperm Quality of Patients With Crohn's Disease
Official title: Impact of Exclusive Enteral Nutrition Therapy on Sperm Quality of Male Patients With Crohn's Disease
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Crohn's Disease
Keywords: Crohn's Disease
semen quality
enteral nutrition
CDAI score higher than 150
Lead sponsor: Jinling Hospital, China
Sponsor class: OTHER
First posted: 2014-09-08
Enrollment: 12
Sex: MALE
Minimum age (years): 18
Maximum age (years): 40
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to investigate the impact of enteral nutrition therapy on sperm quality of patients with crohn's disease.

Detailed description: The highest age- and sex-adjusted incidence rates for Crohn's Disease (CD) occur during the peak reproductive years. In addition, gastroenterologists frequently advise and manage patients with CD who desire to conceive. Enteral nutrition therapy is effective for induction and maintenance of remission in reproductive age men with CD. However, there is no available data on the effects of enteral nutrition therapy on semen quality. The purpose of this study is to investigate the impact of enteral nutrition therapy on sperm quality of patients with CD.

Eligibility criteria: Inclusion Criteria:

* Clinical diagnosis of Crohn' Disease
* Male patients
* Age: 18-40 years old
* Receive 3-months exclusive enteral nutrition therapy

Exclusion Criteria:

* Used any experimental therapy in the 8 weeks before study entry date
* Had previously documented problems with male reproductive health, such as low sperm count, impotence, or malignancy
* The use of concomitant medication including sulphasalazine, 5-aminosalicylic acid or other immune-suppressives.
* Unable to complete the 3-months exclusive enteral nutrition therapy.

Primary outcomes:
measure: Sperm motility
timeFrame: Up to 3 months
Secondary outcomes:
measure: Crohn's Disease Activity Index
timeFrame: Up to 3 months
Other outcomes:
Locations:
city: Nanjing
country: China
facility: Department of General Surgery, Jinling Hospital
state: Jiangsu
Study officials:
References:
Clinical trial NCT06875362: Probiotic LR08 Improves Gut and Metabolism
Official title: Safety and Efficacy of LR08 in Modulating Gut Microbiota and Improving Metabolic Health in Healthy Adults: A Clinical Study
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: NA
Conditions: Healthy Adults
Keywords: Probiotics
Efficacy
Safety
Gut Microbiota
Immune Function
Lead sponsor: Wecare Probiotics Co., Ltd.
Sponsor class: INDUSTRY
First posted: 2025-03-13
Enrollment: 50
Sex: ALL
Minimum age (years): 18
Maximum age (years): 45
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Evaluate the efficacy and safety of LR08 as a dietary supplement compared to a placebo in enhancing intestinal health and immune function in healthy adults.


Eligibility criteria: Inclusion Criteria:

1. Willing to attend 3 follow-up visits during the intervention period
2. Agree to provide blood, urine, and stool samples twice during the intervention period
3. Good eyesight, able to read and write, and capable of wearing glasses if needed
4. Good hearing and able to fully comprehend all instructions during the intervention

Exclusion Criteria:

1. Presence of digestive diseases, particularly gastrointestinal disorders (e.g., celiac disease, ulcerative colitis, Crohn's disease)
2. History of serious neurological conditions (e.g., epilepsy, stroke, severe head trauma, meningitis within the last 10 years, brain surgery, brain tumor, or prolonged coma-not including general anesthesia)
3. History of or currently receiving treatment for mental health disorders such as alcohol/drug/substance abuse, schizophrenia, psychosis, or bipolar disorder
4. Currently taking medication for depression or low mood
5. Presence of internal organ failure (e.g., heart, liver, or kidney failure)
6. History of radiation therapy or chemotherapy treatments
7. Underwent general anesthesia within the past three years or are scheduled for general anesthesia within the next 3 months during the trial period
8. History of hepatitis (B or C), HIV, or syphilis

Primary outcomes:
measure: Changes in Immune Function
timeFrame: Week 0 and Week 8
Secondary outcomes:
Other outcomes:
Locations:
city: Zhengzhou
country: China
facility: Xu fei
state: Henan
Study officials:
References:
Clinical trial NCT01216462: Registry of Acute Coronary Syndromes in the Lazio Region of Italy
Official title: First Prospective Observational Registry of the Lazio Regional Network for Acute Coronary Syndromes
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Acute Coronary Syndromes
Keywords: Acute Coronary Syndrome
Lead sponsor: San Filippo Neri General Hospital
Sponsor class: OTHER
Collaborators: name: Associazione Nazionale Medici Cardiologi Ospedalieri
First posted: 2010-10-07
Enrollment: 3000
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Consecutive patients with ACS admitted to CCU of 15 hospitals of the Lazio Region of Italy.

Brief summary: The NET-SCA Registry has been designed to document and evaluate the clinical epidemiology and current management of Acute Coronary Syndromes in the Lazio Region of Italy.

Detailed description: Lazio is a region of central Italy with a resident population of about 5,600,000. The NET-SCA Registry has been designed to document and evaluate the current presentation and clinical management of Acute Coronary Syndromes (ACS) in this specific regional area of Italy. All consecutive patients with ACS admitted to CCU of 15 hospitals of the Lazio Region will be included in the registry.

Eligibility criteria: Inclusion Criteria:

* admission to CCU for ACS

Exclusion Criteria:

* ACS due to major extracardiac causes (i.e. traumatic)

Primary outcomes:
measure: Total Mortality
timeFrame: 12 months
Secondary outcomes:
measure: Cardiovascular Mortality
timeFrame: 12 months
measure: New admissions of ACS
timeFrame: 12 months
measure: New admissions for heart failure
timeFrame: 12 months
measure: New admissions for coronary revascularization
timeFrame: 12 months
Other outcomes:
Locations:
city: Ostia
country: Italy
facility: Ospedale GG Grassi
state: Roma
city: Rome
country: Italy
facility: Ospedale "G.B. Grassi"
city: Rome
country: Italy
facility: San Filippo Neri Hospital
city: Rome
country: Italy
facility: Ospedale "S. Eugenio"
city: Rome
country: Italy
facility: Ospedale "Sandro Pertini"
city: Rome
country: Italy
facility: Policlinico Casilino
city: Rome
country: Italy
facility: Ospedale "Madre Giuseppina Vannini"
city: Rome
country: Italy
facility: Ospedale FBF "Isola Tiberina"
Study officials:
affiliation: San Filippo Neri Hospital, Rome, Italy
name: Furio Colivicchi, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01970462: Use of Sitagliptin for Stress Hyperglycemia or Mild Diabetes Following Cardiac Surgery
Official title: Use of Sitagliptin for Stress Hyperglycemia or Mild Diabetes Following Cardiac Surgery
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE4
Conditions: Diabetes Mellitus, Type 2
Hyperglycemia
Lead sponsor: Ohio State University
Sponsor class: OTHER
First posted: 2013-10-28
Enrollment: 8
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This is a randomized controlled trial to determine the safety and efficacy of Sitagliptin in patients with stress hyperglycemia or mild diabetes following cardiac surgery. Patients will receive Sitagliptin or placebo. Sitagliptin may be of particular use in this patient population due to the effects on hepatic glucose production (a major feature of SH), safety (lack of contra-indications for heart failure or renal failure and no hypoglycemia), and tolerability. The secondary objective of this study is to determine whether the management of patients with persistent insulin requirements following cardiac surgery differs among patients with stress hyperglycemia or mild diabetes.


Eligibility criteria: Inclusion Criteria:

* Either of the following: Mild Diabetes Mellitus or Stress Hyperglycemia
* AND:
* Cardiac Surgery
* Insulin Requirement between 8-30 units subcutaneous on post-op day 3 or later off pressors, off enteral feeding, extubated OR glucose \>150 mg/dL at least twice in a 24 hour period (\>4 hours apart) and otherwise not requiring basal insulin

Exclusion Criteria:

* use of pressors, mechanical ventilation, or enteral or parenteral feeding within previous 12 hours
* glucocorticoids in doses exceeding the equivalent of Prednisone 10 mg/day within the previous 48 hours
* left ventricular assist device
* percutaneous or laparoscopic surgery
* end stage renal disease
* end stage liver disease
* history of pancreatitis
* type 1 diabetes
* pregnancy
* unable to give consent in english
* no phone
* prisoners
* less than 18 years of age

Primary outcomes:
measure: Difference in Fasting Glucose
timeFrame: 6 weeks
Secondary outcomes:
Other outcomes:
measure: Self Monitored Blood Glucose
timeFrame: 2 weeks
measure: Adherence
timeFrame: 6 weeks
measure: Hypoglycemia
timeFrame: 6 weeks
Locations:
city: Columbus
country: United States
facility: The Ohio State University Wexner Medical Center
state: Ohio
Study officials:
affiliation: Ohio State University
name: Kathleen M Dungan, MD, MPH
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05926362: Capillary-Venous Paired Data Collection
Official title: Capillary-Venous Paired Data Collection
Study type: OBSERVATIONAL
Overall status: NOT_YET_RECRUITING
Conditions: Oncology
Lead sponsor: Entia Ltd
Sponsor class: INDUSTRY
First posted: 2023-07-03
Enrollment: 800
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients who are currently receiving standard of care systemic anti-cancer therapy (chemotherapy, immunotherapy, endocrine and targeted therapy) for solid organ malignancy and have received at least one cycle.

Brief summary: Capillary-venous paired data collection.

Detailed description: An iterative data collection study to continuously assess the performance of our Entia Liberty device with cancer patients. Our device enables a full blood count from a finger prick sample. The participants enrolled in the study will attend the study site for their routine venepuncture blood test. Once enrolled, they will have a finger prick test obtained by a Healthcare Professional (trained member of the clinical research team) to be tested on an Entia Liberty device. Within 4 hours of that same participant's routine venepuncture, a small amount of blood from the venepuncture will be also tested on a second Entia Liberty device in the laboratory. All the results from the capillary finger prick Liberty test, routine venepuncture blood test (gold standard reference method) and the venous blood Liberty test will be compared against each other to regularly assess that the improvements made on the measurement system of the device is sufficient.

Eligibility criteria: Inclusion Criteria:

* Age \>18 years old at the time of study entry
* Currently receiving standard of care systemic anti-cancer therapy (chemotherapy, immunotherapy, endocrine and targeted therapy) for solid organ malignancy and has received at least one cycle of treatment
* Scheduled to be undergoing routine venous laboratory blood tests as part of standard of care
* Can provide written informed consent

Exclusion Criteria:

* History of haematological malignancy
* Inadequate use and understanding of the English language, requiring a translator

Primary outcomes:
measure: Coefficient of Variance of the difference between the lab results and the Liberty results
timeFrame: 3 years
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT00004762: Phase II Pilot Study of Cladribine (2-Chlorodeoxyadenosine; 2-CdA) for Early Stage Primary Sclerosing Cholangitis
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Cholangitis, Sclerosing
Keywords: gastrointestinal disorders
primary sclerosing cholangitis
rare disease
Lead sponsor: Office of Rare Diseases (ORD)
Sponsor class: NIH
Collaborators: name: Scripps Clinic
First posted: 2000-02-25
Enrollment: 5
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Primary purpose: TREATMENT

Brief summary: OBJECTIVES:

I. Evaluate the effects of cladribine (2-chlorodeoxyadenosine; 2-CdA) on biochemical, radiologic, and histologic parameters in patients with early stage primary sclerosing cholangitis.

Detailed description: PROTOCOL OUTLINE:

Patients are treated with subcutaneous injections of cladribine (2-chlorodeoxyadenosine; 2-CdA) for 5 consecutive days every month for 3 months.

Eligibility criteria: PROTOCOL ENTRY CRITERIA:

--Disease Characteristics--

Stage I-III primary sclerosing cholangitis

Radiologically and pathologically documented

No concomitant liver disease, e.g.:

* Viral hepatitis
* Autoimmune hepatitis
* Primary biliary cirrhosis
* Cirrhosis
* Portal hypertension or associated complications
* Jaundice caused by dominant stricture

--Prior/Concurrent Therapy--

No concurrent immunosuppressives

--Patient Characteristics--

Hematopoietic:

* Absolute neutrophil count at least 2500/mm3
* Platelet count at least 100,000/mm3
* Hemoglobin at least 10 g/dL

Other:

* No active infection
* No fistula abscess
* No active inflammatory bowel disease
* Quiescent disease allowed, including: Chronic ulcerative colitis Crohn's disease
* No other significant immunologic disorder
* No active malignancy
* No active alcohol or drug abuse
* No pregnant or nursing women
* Effective contraception required of fertile patients

Endoscopic retrograde cholangiopancreatography within 36 months prior to registration

Liver biopsy within 12 months prior to registration

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: Scripps Clinic
name: Paul J. Pockros
role: STUDY_CHAIR
References:
Clinical trial NCT00244062: Healthy Moms Alcohol Intervention
Official title: "Brief Alcohol Intervention: The Healthy Moms Project."
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Fetal Alcohol Syndrome
Pregnancy
Alcoholism
Lead sponsor: University of Wisconsin, Madison
Sponsor class: OTHER
Collaborators: name: National Institutes of Health (NIH)
First posted: 2005-10-25
Enrollment: 250
Sex: FEMALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL

Brief summary: The study proposes to test the efficacy of a primary care-based brief intervention with women who resumed heavy drinking during the post-partum period and who used alcohol during a previous pregnancy. The trial will also examine the effects of tobacco use, illicit drug use, depression and domestic violence on alcohol use.


Eligibility criteria: Inclusion Criteria:

* Women of childbearing age (18-40) who drank alcohol during their previous pregnancy and who report drinking above recommended limits in the post partum period.

Exclusion Criteria:

* N/A

Primary outcomes:
measure: The aim is to conduct a randomized test of the efficacy of brief physician/nurse advice in reducing alcohol use, alcohol-related harm, and fetal alcohol exposure in subsequent pregnancies in a sample of high-risk post partum pts.
Secondary outcomes:
measure: To est. the prevalence of drinking in ethnic div. pop. post partum women who are pts in 60 practices in Dane, Waukesha, and Milwaukee counties;the effect of age, race, tobacco use, marital status, partner alcohol use, and readiness-to-change;
Other outcomes:
Locations:
Study officials:
affiliation: University of Wisconsin, Madison
name: Michael Fleming, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04896762: Extrapulmonary Presentations of COVID-19 Patients
Official title: Extrapulmonary Presentation of COVID-19 Patients During the Second Wave
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: COVID-19
Keywords: extrapulmonary presentation
pulmonary
Lead sponsor: Sohag University
Sponsor class: OTHER
First posted: 2021-05-21
Enrollment: 948
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: patients presented at a triage point in a tertiary health care facility with a suspected covid 19 disease.

Brief summary: An observational study about the extrapulmonary presentations of COVID-19 patients during the second wave of the pandemic.

Detailed description: a prospective observational study that aimed at

1. provide an overview about the prevalence of extra-pulmonary presentation of COVID-19 during the second wave of the pandemic and
2. Detection of the most frequent affected systems with comparison between the pulmonary and extrapulmonary presentation of COVID 19 as regard patient demographics, comorbidity and level of care needed.

Eligibility criteria: Inclusion Criteria:

* all patient with confirmed covid 19 disease presented to our health facility during the second wave of the pandemic

Exclusion Criteria:

* other diagnosis than covid 19 as a primary cause of presentation of the patient

Primary outcomes:
measure: extrapulmonary presentation in COVID-19
timeFrame: Baseline presentation of confirmed cases with COVID-19
Secondary outcomes:
Other outcomes:
Locations:
city: Sohag
country: Egypt
facility: Sohag University
Study officials:
References:
citation: Dong E, Du H, Gardner L. An interactive web-based dashboard to track COVID-19 in real time. Lancet Infect Dis. 2020 May;20(5):533-534. doi: 10.1016/S1473-3099(20)30120-1. Epub 2020 Feb 19. No abstract available.
citation: Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X, Cheng Z, Yu T, Xia J, Wei Y, Wu W, Xie X, Yin W, Li H, Liu M, Xiao Y, Gao H, Guo L, Xie J, Wang G, Jiang R, Gao Z, Jin Q, Wang J, Cao B. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020 Feb 15;395(10223):497-506. doi: 10.1016/S0140-6736(20)30183-5. Epub 2020 Jan 24.
citation: Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, Liu L, Shan H, Lei CL, Hui DSC, Du B, Li LJ, Zeng G, Yuen KY, Chen RC, Tang CL, Wang T, Chen PY, Xiang J, Li SY, Wang JL, Liang ZJ, Peng YX, Wei L, Liu Y, Hu YH, Peng P, Wang JM, Liu JY, Chen Z, Li G, Zheng ZJ, Qiu SQ, Luo J, Ye CJ, Zhu SY, Zhong NS; China Medical Treatment Expert Group for Covid-19. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med. 2020 Apr 30;382(18):1708-1720. doi: 10.1056/NEJMoa2002032. Epub 2020 Feb 28.
Clinical trial NCT01943162: Enhanced Cognitive Rehabilitation to Treat Comorbid TBI and PTSD
Official title: Enhanced Cognitive Rehabilitation to Treat Comorbid TBI and PTSD
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: PTSD With a History of Mild to Moderate TBI
Lead sponsor: San Diego Veterans Healthcare System
Sponsor class: FED
Collaborators: name: Congressionally Directed Medical Research Programs
First posted: 2013-09-16
Enrollment: 108
Sex: ALL
Minimum age (years): 18
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This study will test a modification of Cognitive Processing Therapy (CPT) for Post-Traumatic Stress Disorder, (PTSD) in which CPT is augmented with compensatory cognitive rehabilitation principles from the Cognitive Symptom Management and Rehabilitation Therapy (CogSMART) intervention to create a hybrid treatment, SMART-CPT. This study investigates the efficacy of SMART-CPT in improving PTSD and post-concussive symptoms, cognition, quality of life, and treatment compliance in those with a history of mild to moderate TBI and persistent cognitive complaints.


Eligibility criteria: Inclusion Criteria:

1) OEF/OIF veteran; 2) Current diagnosis of PTSD; 3) History of mild-to-moderate TBI; 4) Subjective cognitive complaints; 5) No anticipated/pending medication changes; 6) Written informed consent to participate in the study. -

Exclusion Criteria:1) Active substance dependence, 2) Suicidal intent or attempt within the previous month; 3) Current psychotic disorder; 4) Dementia; 5) Non-English speaking; 6) Participation in other intervention studies.

-

Primary outcomes:
measure: PTSD Checklist
timeFrame: change from baseline PTSD Checklist at 12 weeks (post-treatment)
Secondary outcomes:
Other outcomes:
Locations:
city: San Diego
country: United States
facility: VA San Diego Healthcare System
state: California
Study officials:
affiliation: VA San Diego
name: Amy Jak, Ph.D.
role: PRINCIPAL_INVESTIGATOR
References: